Testing New Treatments for Ovarian and Endometrial Cancer in Women

Recruiting · Phase 2 · Recurrent Endometrial Carcinoma and related conditions · 36 states

Check if I qualify View on ClinicalTrials.gov

About this trial

This clinical trial looks at how well two treatments work for women with ovarian or endometrial cancer that has returned or is still present after treatment. The study compares selumetinib alone to selumetinib combined with olaparib. Selumetinib blocks certain enzymes that tumors need to grow. Olaparib keeps cancer cells from repairing their damaged DNA, which may help them die. The goal is to see if the combination treatment helps more than selumetinib alone.

This is a Phase 2 trial, which means it is looking at how well the treatments work and how safe they are. The trial is regulated by the FDA and aims to include about 165 participants.

Who can join

This trial is open to women aged 18 and older who have certain types of ovarian or endometrial cancer with specific genetic mutations. Participants need to have measurable tumors and must be willing to undergo biopsies. They should have already progressed after their first treatment. The trial team will confirm eligibility before anyone joins.

Conditions

Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma

Age group

Adult, Older adult

Sex

Female

The study team makes the final call on eligibility.

What happens in the study

Participants will be randomly put into one of two groups. One group will receive selumetinib and olaparib together. The other group will receive selumetinib only. Everyone will take their medications for 28 days at a time, and the trial includes tests like biopsies and scans to monitor their health throughout the study.